Farrah Dean - BriaCell Therapeutics Mang Devel
| BCTXW Stock | USD 0.43 0.08 22.86% |
Insider
Farrah Dean is Mang Devel of BriaCell Therapeutics Corp
| Address | Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1 |
| Phone | 604-921-1810 |
| Web | https://briacell.com |
BriaCell Therapeutics Management Efficiency
The company has return on total asset (ROA) of (1.2611) % which means that it has lost $1.2611 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.0601) %, meaning that it generated substantial loss on money invested by shareholders. BriaCell Therapeutics' management efficiency ratios could be used to measure how well BriaCell Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to climb to 5.08 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.64). At this time, BriaCell Therapeutics' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 1.3 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 1.2 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kirk Coleman | Tff Pharmaceuticals | 50 | |
| Mark Lappe | Inhibrx | 57 | |
| Dale Christensen | Tff Pharmaceuticals | N/A | |
| Anthony Hickey | Tff Pharmaceuticals | N/A | |
| Robert MBA | Eliem Therapeutics | 56 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Paul Manley | Tff Pharmaceuticals | N/A | |
| Susan MS | Eliem Therapeutics | N/A | |
| , MBA | Molecular Partners AG | 51 | |
| DVM MS | Lantern Pharma | N/A | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| JD MSc | Cue Biopharma | 61 | |
| James JD | Eliem Therapeutics | 58 | |
| Steven Almo | Cue Biopharma | 63 | |
| Quinn Deveraux | Inhibrx | N/A | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Glenn Mattes | Tff Pharmaceuticals | 67 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Dr III | Cue Biopharma | 48 | |
| Christopher Cano | Tff Pharmaceuticals | 53 | |
Management Performance
| Return On Equity | -2.06 | ||||
| Return On Asset | -1.26 |
BriaCell Therapeutics Leadership Team
Elected by the shareholders, the BriaCell Therapeutics' board of directors comprises two types of representatives: BriaCell Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BriaCell. The board's role is to monitor BriaCell Therapeutics' management team and ensure that shareholders' interests are well served. BriaCell Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BriaCell Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William MD, President CEO | ||
| FACP MD, Founder Director | ||
| MD FACP, Principal Founder | ||
| Miguel LopezLago, Chief Officer | ||
| Farrah Dean, Mang Devel | ||
| MD MPH, Chief Officer |
BriaCell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BriaCell Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.06 | ||||
| Return On Asset | -1.26 | ||||
| Number Of Shares Shorted | 2.94 K | ||||
| EBITDA | (4.79 M) | ||||
| Net Income | (4.93 M) | ||||
| Total Debt | 8.56 M | ||||
| Book Value Per Share | (0.13) X | ||||
| Cash Flow From Operations | (24.13 M) | ||||
| Beta | 1.82 | ||||
| Market Capitalization | 48.08 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BriaCell Stock Analysis
When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.